Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of AB002 in ESRD Patients on Hemodialysis
NCT03963895Phase 2Completed
- Sponsor
- Aronora, Inc.
- Start
- Jul 2019
- Primary completion
- Dec 2020
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AB002 in thrombosis, sponsored by Aronora, Inc. Primary endpoints: Treatment-emergent Adverse Events at 22 days, Bleeding at the Hemodialysis Vascular Access Site at Day 3 and 6 more. Started Jul 2019; status: completed.
02
Drugs
AB002
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT03963895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03963895.